2025
Molecular Diagnosis of Gestational Trophoblastic Disease
Hui P. Molecular Diagnosis of Gestational Trophoblastic Disease. 2025, 217-251. DOI: 10.1007/978-3-031-83545-2_14.Peer-Reviewed Original ResearchGestational trophoblastic tumorsInternational Collaboration on Cancer ReportingGestational trophoblastic diseaseHydatidiform MoleDevelopment of gestational trophoblastic tumorsPolymerase chain reactionSTR genotypingSubtypes of hydatidiform moleShort tandem repeat (STRTrophoblastic tumorTrophoblastic diseaseDiagnostic workupPathological diagnosisPrognostic riskTumor developmentClinical sensitivityGerm cellsHydatidiformMolecular diagnosisAncillary toolSomatic originClinical practiceGenetic compositionSTR analysisCancer reporting
2022
Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC).
Navani V, Ernst M, Wells C, Yuasa T, Takemura K, Donskov F, Basappa N, Schmidt A, Pal S, Meza L, Wood L, Ernst D, Szabados B, McKay R, Weickhardt A, Suárez C, Kapoor A, Lee J, Choueiri T, Heng D. Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC). Journal Of Clinical Oncology 2022, 40: 310-310. DOI: 10.1200/jco.2022.40.6_suppl.310.Peer-Reviewed Original ResearchAssociated with responseCytoreductive nephrectomyIpi-nivoLung metastasesMetastatic renal cell carcinomaPresence of lung metastasesResponse to first-lineImmunotherapy combination regimensMedian overall survivalRenal cell carcinomaPredictors of responseEndothelial growth factorIpilimumab-nivolumabSarcomatoid histologyRECIST v1.1Combination regimensOverall survivalCombination therapyCell carcinomaFirst-lineResponse of CRNon-respondersPrognostic riskClinical variablesPatient counseling
2019
Non-invasive Multimodality Cardiovascular Imaging of the Right Heart and Pulmonary Circulation in Pulmonary Hypertension
Hur DJ, Sugeng L. Non-invasive Multimodality Cardiovascular Imaging of the Right Heart and Pulmonary Circulation in Pulmonary Hypertension. Frontiers In Cardiovascular Medicine 2019, 6: 24. PMID: 30931315, PMCID: PMC6427926, DOI: 10.3389/fcvm.2019.00024.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMean pulmonary arterial pressureRight heart catheterizationPulmonary hypertensionRight ventricleEvaluation of PHMultimodality cardiovascular imagingPulmonary arterial pressurePulmonary arterial vasculatureNon-invasive imaging methodMillimeters of mercuryHeart catheterizationArterial pressurePrognostic riskRight heartNon-invasive imagingPatient survivalRV structurePulmonary circulationSeverity stratificationEarly initiationArterial vasculatureFunctional assessmentMortality rateRH dysfunctionTreatment management
2018
Comparison of Residual Risk–Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies
Wei W, Kurita T, Hess KR, Sanft T, Szekely B, Hatzis C, Pusztai L. Comparison of Residual Risk–Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies. JAMA Oncology 2018, 4: e175092-e175092. PMID: 29372234, PMCID: PMC5885272, DOI: 10.1001/jamaoncol.2017.5092.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantEligibility DeterminationFemaleHumansLymph NodesLymphatic MetastasisMiddle AgedNeoplasm Recurrence, LocalNeoplasm, ResidualPatient SelectionPrognosisRandomized Controlled Trials as TopicReproducibility of ResultsResearch DesignRetrospective StudiesRisk FactorsSurvival AnalysisTrastuzumabTumor BurdenWatchful WaitingYoung AdultConceptsTumor sizeAdjuvant trialsEligibility criteriaNodal statusClinical trialsResidual riskEarly-stage breast cancerAdjuvant clinical trialsBaseline prognostic riskFuture adjuvant trialsResidual risk estimatesRisk of recurrenceBreast cancer therapyRisk thresholdTrial powerClinical trial powerTrial eligibilityAdjuvant therapyCare therapyConsecutive patientsPrognostic riskPatient eligibilityTrial populationPatient cohortControl arm
2017
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype
Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. Journal Of Clinical Oncology 2017, 35: jco.2015.63.101. PMID: 28135148, PMCID: PMC5455352, DOI: 10.1200/jco.2015.63.1010.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideDisease-Free SurvivalDoxorubicinEpirubicinFemaleFluorouracilHumansMiddle AgedNeoadjuvant TherapyNeoplasm, ResidualPaclitaxelPhenotypePrognosisProspective StudiesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRisk AssessmentSurvival RateTime FactorsTrastuzumabTumor BurdenConceptsResidual cancer burdenPhenotypic subsetsNeoadjuvant chemotherapyValidation cohortPrognostic riskCancer burdenRCB classBreast cancerRCB indexRelapse-free survival estimatesRelapse-free survival rateHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Hormone receptorsOriginal development cohortGrowth factor receptor 2Clinical-pathologic variablesKaplan-Meier analysisLong-term prognosisLog-rank testIndependent validation cohortBreast cancer subtypesLong-term survivalFactor receptor 2Concurrent trastuzumab
2015
Long‐Term Prognostic Risk in Lower Extremity Peripheral Arterial Disease as a Function of the Number of Peripheral Arterial Lesions
Smolderen KG, van Zitteren M, Jones PG, Spertus JA, Heyligers JM, Nooren MJ, Vriens PW, Denollet J. Long‐Term Prognostic Risk in Lower Extremity Peripheral Arterial Disease as a Function of the Number of Peripheral Arterial Lesions. Journal Of The American Heart Association 2015, 4: e001823. PMID: 26504149, PMCID: PMC4845133, DOI: 10.1161/jaha.115.001823.Peer-Reviewed Original ResearchMeSH KeywordsAgedArteriesChi-Square DistributionDisease ProgressionFemaleHumansKaplan-Meier EstimateLower ExtremityMaleMiddle AgedMultivariate AnalysisNetherlandsPeripheral Arterial DiseasePredictive Value of TestsPrognosisProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsUltrasonography, Doppler, DuplexConceptsLower extremity lesionsPeripheral artery diseasePAD patientsAdverse prognosisExtremity lesionsLower extremity peripheral arterial diseaseSimple risk stratification toolDuplex ultrasound testingPeripheral arterial lesionsClinical risk factorsPeripheral arterial diseaseFirst adverse eventGreater disease burdenLong-term prognosisRisk stratification toolPAD diagnosisAdverse eventsProspective cohortArtery diseaseArterial diseaseArterial lesionsPrognostic riskDisease burdenIndependent associationRisk factors
2014
Gaps in Perception Between Patients and Physicians Regarding Symptomatology and Treatment Attitudes for Myeloproliferative Neoplasms: MPN LANDMARK SURVEY
Mesa R, Miller C, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Dubinski D, Boyle J, Mascarenhas J. Gaps in Perception Between Patients and Physicians Regarding Symptomatology and Treatment Attitudes for Myeloproliferative Neoplasms: MPN LANDMARK SURVEY. Blood 2014, 124: 4827. DOI: 10.1182/blood.v124.21.4827.4827.Peer-Reviewed Original ResearchPatient-physician communicationIncyte CorporationPrognostic risk scoreImportant treatment goalMost patientsDisease burdenMajority of physiciansTreatment goalsMyeloproliferative neoplasmsPolycythemia veraEssential thrombocythemiaPrognostic riskPhysicians' perceptionsSpeakers bureauRisk scoreDisease settingsPoor patient-physician communicationFourth of patientsPrimary treatment recommendationLandmark surveyThird of patientsOverall managementDisease-related symptomsAdvisory CommitteeYears of age
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply